StemDAO is engineering mesenchymal stem cells (MSCs) to adopt an anti-inflammatory phenotype, optimizing their exosomes and secretome for therapeutic use. These extracellular vesicles (EVs) target age-related decline.
Based on strong preclinical data and insights from global research over the past decade, we have identified three key therapeutic targets:
Our proprietary polarized MSC-derived EVs modulate neuroinflammation, enhance neurogenesis, and improve cognitive function. Out preclinical data shows that intranasal administration of these EVs improves spatial learning and memory in aged mice, with selective targeting of inflamed brain regions.
Our MSC-derived EVs reverse senescence-associated fibroblast dysfunction. When combined with microneedling, these EVs can penetrate deeper into the skin, enhancing wound healing and elasticity. This approach provides a fast track for clinical translation in aesthetic and dermatological applications.
EVs from young tissues reduce systemic inflammation and cellular senescence, which drive multi-organ dysfunction in aging. Preclinical data show lifespan extension and improved immune homeostasis following EV infusion in mice. StemDAO develops polarized MSC-derived EVs for intravenous administration, targeting inflammatory and metabolic aging pathways.
To establish this therapy as a viable product, we are focused on:
Multi-omics characterization of EV bioactive components.
Optimizing the therapies, refining their regenerative potential for human trials.
Development of reproducible, cost-effective production methods for large-scale EV generation.
Further validation in aging models to assess systemic effects and therapeutic potential.
Deployment through grey market access, special jurisdiction approvals, and medical tourism to accelerate availability.
The trial will measue LinAge2 and cognitive performance in a cohort of healthy elderly individuals @ the National University of Singapore.
$STEM launch
Scale up production
Start Phase 1 trial
Final results
2nd Raise
Phase IIa trial commences in Singapore
Stem cell and extracellular vesicle (EV) therapies are reshaping regenerative medicine. Thousands of clinics worldwide offer these treatments, with patients traveling across the globe to access them—often paying tens of thousands of dollars for a single procedure. Yet, despite promising preclinical and clinical outcomes, regulatory barriers have stalled approval in major markets like the U.S., forcing these therapies into a fragmented grey market.
StemDAO exists to accelerate access to high-quality regenerative treatments by advancing the development of clinically validated, standardized, and ethically governed therapies. We focus on stem cell-derived EVs, secretomes, and related modalities—leveraging their unique ability to repair, regenerate, and enhance cellular function.
